Evidence for acute neurotoxicity after chemotherapy

Petzold, Axel; Mondria, Tjeerd; Kühle, Jens; Rocca, Maria A.; Cornelissen, Jan J.; Boekhorst, Peter te; Löwenberg, Bob; Giovannoni, Gavin; Filippi, Massimo; Kappos, Ludwig; Hintzen, Rogier Q.

doi:10.1002/ana.22169

Cited by 56 publications

(68 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We previously reported a median NfH SMI35 concentration of 0.21 ng/mL in CSF of a biologically representative population recruited from the UCLH Emergency and Accident Department. This exceeds the amount found in serum by far, where NfH SMI35 levels were below the detection limit in a group of healthy volunteers [23]. Further knowledge on release, kinetics and clearance of NfH across the body fluid compartments is required.…”

Section: Discussionmentioning

confidence: 75%

Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign

et al. 2011

Self Cite

View full text Add to dashboard Cite

Serological biomarkers which enable quick and reliable diagnosis or measurement of the extent of irreversible brain injury early in the course of stroke are eagerly awaited. Neurofilaments (Nf) are a group of proteins integrated into the scaffolding of the neuronal and axonal cytoskeleton and an established biomarker of neuroaxonal damage. The Nf heavy chain (NfH SMI35 ) was assessed together with brain-specific astroglial proteins GFAP and S100B in hyperacute stroke (6 and 24 h from symptom onset) and daily for up to 6 days. Twenty-two patients with suspected stroke (median NIHSS 8) were recruited in a prospective observational study. Evidence for an ischaemic or haemorrhagic lesion on neuroimaging was found in 18 (ischaemia n = 16, intracerebral haemorrhage n = 2). Serum NfH SMI35 levels became detectable within 24 h post-stroke (P \ 0.0001) and elevated levels persisted over the study course. While GFAP was not detectable during the entire course, S100B levels peaked at the end of the observation period. The data indicate that significant in vivo information on the pathophysiology of stroke may be obtained by the determination of NfH SMI35 . Further studies are required to evaluate whether NfH SMI35 in hyperacute stroke reflects the extent of focal ischaemic injury seen on neuroimaging or is a consequence of more diffuse neuroaxonal damage.

show abstract

Section: Discussionmentioning

confidence: 75%

Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…The quantitative contribution of such non-CNS derived protein was found to be negligible for neurological biomarker studies (Petzold et al, 2010).…”

Section: 4mentioning

confidence: 98%

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

Petzold

2015

Brain Research

Self Cite

View full text Add to dashboard Cite

This review on the role of glial fibrillary acidic protein (GFAP) as a biomarker for astroglial pathology in neurological diseases provides background to protein synthesis, assembly, function and degeneration. Qualitative and quantitative analytical techniques for the investigation of human tissue and biological fluid samples are discussed including partial lack of parallelism and multiplexing capabilities. Pathological implications are reviewed in view of immunocytochemical, cell-culture and genetic findings. Particular emphasis is given to neurodegeneration related to autoimmune astrocytopathies and to genetic gain of function mutations. The current literature on body fluid levels of GFAP in human disease is summarised and illustrated by disease specific meta-analyses. In addition to the role of GFAP as a diagnostic biomarker for chronic disease, there are important data on the prognostic value for acute conditions. The published evidence permits to classify the dominant GFAP signatures in biological fluids. This classification may serve as a template for supporting diagnostic criteria of autoimmune astrocytopathies, monitoring disease progression in toxic gain of function mutations, clinical treatment trials (secondary outcome and toxicity biomarker) and provide prognostic information in neurocritical care if used within well defined time-frames.

show abstract

“…Of the 38 articles, 8 were clinical trials [14,20,26,27,31,39,50,51] and 30 were observational studies [15][16][17][18][19][21][22][23][24][25][28][29][30][32][33][34][35][36][37][38][40][41][42][43][44][45][46][47][48][49]. Nine studies included a healthy control arm [15,21,23,27,32,40,[48][49][50].…”

Section: Overall Study Descriptionmentioning

confidence: 99%

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis

Vollmer

Signorovitch

Huynh

et al. 2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Evidence for acute neurotoxicity after chemotherapy

Abstract: Neurotoxicity is an unwanted acute side effect of aggressive chemotherapy.

Cited by 56 publications

References 53 publications

Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign

Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign

Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis

Contact Info

Product

Resources

About